Pharmacological treatment of mechanical edema: a randomized controlled trial about the effects of mesoglycan.
Identifieur interne : 002B43 ( PubMed/Checkpoint ); précédent : 002B42; suivant : 002B44Pharmacological treatment of mechanical edema: a randomized controlled trial about the effects of mesoglycan.
Auteurs : T. Viliani [Italie] ; M. Scarselli ; A. Pieri ; M. Gatti ; M. Santini ; P. PasquettiSource :
- European journal of physical and rehabilitation medicine [ 1973-9087 ] ; 2009.
Descripteurs français
- KwdFr :
- Adulte, Adulte d'âge moyen, Femelle, Glycosaminoglycanes (usage thérapeutique), Humains, Insuffisance veineuse (traitement médicamenteux), Jambe (), Loi du khi-deux, Mâle, Oedème (traitement médicamenteux), Résultat thérapeutique, Statistique non paramétrique, Sujet âgé, Sujet âgé de 80 ans ou plus, Techniques de physiothérapie.
- MESH :
- traitement médicamenteux : Insuffisance veineuse, Oedème.
- usage thérapeutique : Glycosaminoglycanes.
- Adulte, Adulte d'âge moyen, Femelle, Humains, Jambe, Loi du khi-deux, Mâle, Résultat thérapeutique, Statistique non paramétrique, Sujet âgé, Sujet âgé de 80 ans ou plus, Techniques de physiothérapie.
English descriptors
- KwdEn :
- MESH :
- chemical , therapeutic use : Glycosaminoglycans.
- blood supply : Leg.
- drug therapy : Edema, Venous Insufficiency.
- Adult, Aged, Aged, 80 and over, Chi-Square Distribution, Female, Humans, Male, Middle Aged, Physical Therapy Modalities, Statistics, Nonparametric, Treatment Outcome.
Abstract
Mechanical edema (MO) is frequently found in a lot of the lower extremities' orthopedic diseases. In absence of deep vein thrombosis, MO is caused by the change in the dynamics of calf muscle pump with venous hypertension and by the change in capillary permeability which offsets the extra-vascular fluid balance resulting in edema formation. The correct treatment includes specific training for musculo-skeletal and gait recovery, together with medical treatment focused on venous endothelium. Little information is available about pharmacological treatment of this condition. Some studies suggest the efficacy of mesoglycan in venous pathology. Aim of this study was to evaluate the clinical efficacy of the pharmacological treatment (mesoglycan 50 mg p.o., twice a day) in patients affected by MO.
PubMed: 19270639
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:19270639Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Pharmacological treatment of mechanical edema: a randomized controlled trial about the effects of mesoglycan.</title><author><name sortKey="Viliani, T" sort="Viliani, T" uniqKey="Viliani T" first="T" last="Viliani">T. Viliani</name><affiliation wicri:level="1"><nlm:affiliation>Recovery and Rehabilitation Agency, University Hospital of Careggi, Florence, Italy. vilianit@aou-careggi.toscana.it</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Recovery and Rehabilitation Agency, University Hospital of Careggi, Florence</wicri:regionArea><wicri:noRegion>Florence</wicri:noRegion></affiliation></author><author><name sortKey="Scarselli, M" sort="Scarselli, M" uniqKey="Scarselli M" first="M" last="Scarselli">M. Scarselli</name></author><author><name sortKey="Pieri, A" sort="Pieri, A" uniqKey="Pieri A" first="A" last="Pieri">A. Pieri</name></author><author><name sortKey="Gatti, M" sort="Gatti, M" uniqKey="Gatti M" first="M" last="Gatti">M. Gatti</name></author><author><name sortKey="Santini, M" sort="Santini, M" uniqKey="Santini M" first="M" last="Santini">M. Santini</name></author><author><name sortKey="Pasquetti, P" sort="Pasquetti, P" uniqKey="Pasquetti P" first="P" last="Pasquetti">P. Pasquetti</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2009">2009</date><idno type="RBID">pubmed:19270639</idno><idno type="pmid">19270639</idno><idno type="wicri:Area/PubMed/Corpus">002F50</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002F50</idno><idno type="wicri:Area/PubMed/Curation">002F50</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002F50</idno><idno type="wicri:Area/PubMed/Checkpoint">002F50</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002F50</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Pharmacological treatment of mechanical edema: a randomized controlled trial about the effects of mesoglycan.</title><author><name sortKey="Viliani, T" sort="Viliani, T" uniqKey="Viliani T" first="T" last="Viliani">T. Viliani</name><affiliation wicri:level="1"><nlm:affiliation>Recovery and Rehabilitation Agency, University Hospital of Careggi, Florence, Italy. vilianit@aou-careggi.toscana.it</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Recovery and Rehabilitation Agency, University Hospital of Careggi, Florence</wicri:regionArea><wicri:noRegion>Florence</wicri:noRegion></affiliation></author><author><name sortKey="Scarselli, M" sort="Scarselli, M" uniqKey="Scarselli M" first="M" last="Scarselli">M. Scarselli</name></author><author><name sortKey="Pieri, A" sort="Pieri, A" uniqKey="Pieri A" first="A" last="Pieri">A. Pieri</name></author><author><name sortKey="Gatti, M" sort="Gatti, M" uniqKey="Gatti M" first="M" last="Gatti">M. Gatti</name></author><author><name sortKey="Santini, M" sort="Santini, M" uniqKey="Santini M" first="M" last="Santini">M. Santini</name></author><author><name sortKey="Pasquetti, P" sort="Pasquetti, P" uniqKey="Pasquetti P" first="P" last="Pasquetti">P. Pasquetti</name></author></analytic><series><title level="j">European journal of physical and rehabilitation medicine</title><idno type="ISSN">1973-9087</idno><imprint><date when="2009" type="published">2009</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Chi-Square Distribution</term><term>Edema (drug therapy)</term><term>Female</term><term>Glycosaminoglycans (therapeutic use)</term><term>Humans</term><term>Leg (blood supply)</term><term>Male</term><term>Middle Aged</term><term>Physical Therapy Modalities</term><term>Statistics, Nonparametric</term><term>Treatment Outcome</term><term>Venous Insufficiency (drug therapy)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Femelle</term><term>Glycosaminoglycanes (usage thérapeutique)</term><term>Humains</term><term>Insuffisance veineuse (traitement médicamenteux)</term><term>Jambe ()</term><term>Loi du khi-deux</term><term>Mâle</term><term>Oedème (traitement médicamenteux)</term><term>Résultat thérapeutique</term><term>Statistique non paramétrique</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Techniques de physiothérapie</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Glycosaminoglycans</term></keywords><keywords scheme="MESH" qualifier="blood supply" xml:lang="en"><term>Leg</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Edema</term><term>Venous Insufficiency</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Insuffisance veineuse</term><term>Oedème</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Glycosaminoglycanes</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Chi-Square Distribution</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Physical Therapy Modalities</term><term>Statistics, Nonparametric</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Femelle</term><term>Humains</term><term>Jambe</term><term>Loi du khi-deux</term><term>Mâle</term><term>Résultat thérapeutique</term><term>Statistique non paramétrique</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Techniques de physiothérapie</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Mechanical edema (MO) is frequently found in a lot of the lower extremities' orthopedic diseases. In absence of deep vein thrombosis, MO is caused by the change in the dynamics of calf muscle pump with venous hypertension and by the change in capillary permeability which offsets the extra-vascular fluid balance resulting in edema formation. The correct treatment includes specific training for musculo-skeletal and gait recovery, together with medical treatment focused on venous endothelium. Little information is available about pharmacological treatment of this condition. Some studies suggest the efficacy of mesoglycan in venous pathology. Aim of this study was to evaluate the clinical efficacy of the pharmacological treatment (mesoglycan 50 mg p.o., twice a day) in patients affected by MO.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19270639</PMID><DateCreated><Year>2009</Year><Month>03</Month><Day>18</Day></DateCreated><DateCompleted><Year>2009</Year><Month>08</Month><Day>20</Day></DateCompleted><DateRevised><Year>2009</Year><Month>03</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1973-9087</ISSN><JournalIssue CitedMedium="Print"><Volume>45</Volume><Issue>1</Issue><PubDate><Year>2009</Year><Month>Mar</Month></PubDate></JournalIssue><Title>European journal of physical and rehabilitation medicine</Title><ISOAbbreviation>Eur J Phys Rehabil Med</ISOAbbreviation></Journal><ArticleTitle>Pharmacological treatment of mechanical edema: a randomized controlled trial about the effects of mesoglycan.</ArticleTitle><Pagination><MedlinePgn>21-9</MedlinePgn></Pagination><Abstract><AbstractText Label="AIM" NlmCategory="OBJECTIVE">Mechanical edema (MO) is frequently found in a lot of the lower extremities' orthopedic diseases. In absence of deep vein thrombosis, MO is caused by the change in the dynamics of calf muscle pump with venous hypertension and by the change in capillary permeability which offsets the extra-vascular fluid balance resulting in edema formation. The correct treatment includes specific training for musculo-skeletal and gait recovery, together with medical treatment focused on venous endothelium. Little information is available about pharmacological treatment of this condition. Some studies suggest the efficacy of mesoglycan in venous pathology. Aim of this study was to evaluate the clinical efficacy of the pharmacological treatment (mesoglycan 50 mg p.o., twice a day) in patients affected by MO.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Forty-four patients with MO, aged 20-89 years, were randomized in two treatment groups: specific physiotherapy (Fkt) alone or physiotherapy plus mesoglycan 50 mg twice a day, per os. The patients were evaluated before treatment (t0), and after 1 month of treatment (t1), measuring ankle joint range of motion (degrees), calf circumference and malleolar circumference (cm), pain Borg CR10 Scale and adapted lymphedema Weiss Scale. Statistical analysis was performed by the Pearson's c2 test and the Mann-Whitney-Wilcoxon test.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">At the final evaluation of the objective and subjective parameters, the mesoglycan effect combined to the Fkt provided statistical differences on nearly all the parameters in comparison with the patients randomised to Fkt alone.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The present study suggest that mesoglycan treatment (50 mg p.o., twice a day) can improve the recovery of MO, and it is well tolerated by the patients. Specific physiotherapy remains the first treatment for the recovery of both muscular pump and correct walking, but the optimal treatment of MO seems to be a synergic approach, including both pharmacological and mobilization programs.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Viliani</LastName><ForeName>T</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Recovery and Rehabilitation Agency, University Hospital of Careggi, Florence, Italy. vilianit@aou-careggi.toscana.it</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scarselli</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Pieri</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Gatti</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Santini</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Pasquetti</LastName><ForeName>P</ForeName><Initials>P</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>03</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>Italy</Country><MedlineTA>Eur J Phys Rehabil Med</MedlineTA><NlmUniqueID>101465662</NlmUniqueID><ISSNLinking>1973-9087</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006025">Glycosaminoglycans</NameOfSubstance></Chemical><Chemical><RegistryNumber>80455-95-4</RegistryNumber><NameOfSubstance UI="C040617">mesoglycan</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016009" MajorTopicYN="N">Chi-Square Distribution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004487" MajorTopicYN="N">Edema</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006025" MajorTopicYN="N">Glycosaminoglycans</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007866" MajorTopicYN="N">Leg</DescriptorName><QualifierName UI="Q000098" MajorTopicYN="Y">blood supply</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D026741" MajorTopicYN="N">Physical Therapy Modalities</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018709" MajorTopicYN="N">Statistics, Nonparametric</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014689" MajorTopicYN="N">Venous Insufficiency</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>3</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>3</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>8</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19270639</ArticleId><ArticleId IdType="pii">R33091979</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Italie</li></country></list><tree><noCountry><name sortKey="Gatti, M" sort="Gatti, M" uniqKey="Gatti M" first="M" last="Gatti">M. Gatti</name><name sortKey="Pasquetti, P" sort="Pasquetti, P" uniqKey="Pasquetti P" first="P" last="Pasquetti">P. Pasquetti</name><name sortKey="Pieri, A" sort="Pieri, A" uniqKey="Pieri A" first="A" last="Pieri">A. Pieri</name><name sortKey="Santini, M" sort="Santini, M" uniqKey="Santini M" first="M" last="Santini">M. Santini</name><name sortKey="Scarselli, M" sort="Scarselli, M" uniqKey="Scarselli M" first="M" last="Scarselli">M. Scarselli</name></noCountry><country name="Italie"><noRegion><name sortKey="Viliani, T" sort="Viliani, T" uniqKey="Viliani T" first="T" last="Viliani">T. Viliani</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002B43 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 002B43 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:19270639
|texte= Pharmacological treatment of mechanical edema: a randomized controlled trial about the effects of mesoglycan.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:19270639" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |